Regeneron Pharmaceuticals Q4 Earnings: Revenue Falls As COVID-19-Related Sales Dwindle
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) earned $12.56 per share for Q4 FY22, down 46% Y/Y, beating the $10.03 Street estimate. Revenues…
Regeneron Pharmaceuticals’s Earnings Outlook
Regeneron Pharmaceuticals (NASDAQ:REGN) is set to give its latest quarterly earnings report on Friday, 2023-02-03. Here’s what investors…
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,300 Today
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 5 years by 8.86% on an annualized basis…
February PDUFA Catalysts Biotech Investors Must Know: Sanofi’s Bleeding Disorder Drug, Regeneron’s Twin Eylea Label Expansions, 3 Delayed Approvals And More
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new molecular entities for the year.
Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch
With a full week of earnings behind us, it’s time to take stock of the fourth-quarter reporting season so far. Overall, the news flow has been mixed, although tech earnings have grossly disappointed.
Regeneron, Sanofi Announced Earlier , Dupixent Recommended For Expanded EU Approval By The CHMP To Treat Children As Young As Six Months Old With Severe Atopic Dermatitis
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for Dupixent® (dupilumab), recommending expanded approval in the European Union (EU) to treat severe atopic dermatitis in children 6 months to 5 years old who are candidates for systemic therapy.
JP Morgan Upgrades Regeneron Pharmaceuticals to Overweight, Announces $850 Price Target
JP Morgan analyst Chris Schott upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) from Neutral to Overweight and announces $850 price target.
Here’s How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 15 years by 18.8% on an annualized basis…
Check Out What Whales Are Doing With REGN
A whale with a lot of money to spend has taken a noticeably bearish stance on Regeneron Pharmaceuticals.
Looking at options history for Regeneron Pharmaceuticals (NASDAQ:REGN) we detected 30 strange trades.
2seventy bio Announces Expanded Translational Collaboration With Regeneron To Develop New Cell Therapy-Based Combinations Dor Solid Tumors; Regeneron To Invest $20M In 2seventy Equity
Collaboration Leverages 2seventy's Platform for T Cell Therapy Research and Development with Regeneron Antibodies and Bispecifics to Explore Multiplex Combination Approaches
Regeneron Investing $20